124 related articles for article (PubMed ID: 38884296)
1. [IMATINIB INDUCED EDEMA].
Olshanskiy D; Ben Varon H; Mouallem M
Harefuah; 2024 Jun; 163(6):397. PubMed ID: 38884296
[TBL] [Abstract][Full Text] [Related]
2. Successful Use of Dasatinib After Liver Transplantation for Imatinib-Induced Fulminant Liver Failure in Chronic Myeloid Leukemia.
Harding DJ; MacQuillan G; Howman R; de Boer B; Adams L; Mitchell A; Jeffrey G
J Clin Oncol; 2016 Apr; 34(11):e97-8. PubMed ID: 25267743
[No Abstract] [Full Text] [Related]
3. Imatinib-induced postoperative periorbital purpura: GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia.
Anzalone CL; Cohen PR; Kurzrock R; Cortes JE
Dermatol Online J; 2014 Jan; 20(1):21242. PubMed ID: 24456946
[TBL] [Abstract][Full Text] [Related]
4. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
Lejniece S; Udre I; Rivkina A
Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
[TBL] [Abstract][Full Text] [Related]
5. How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.
Ferrero D; Cerrano M; Crisà E; Aguzzi C; Giai V; Boccadoro M
Br J Haematol; 2017 Feb; 176(4):669-671. PubMed ID: 26914729
[No Abstract] [Full Text] [Related]
6. Imatinib Intolerance Is Associated With Blastic Phase Development in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.
Ángeles-Velázquez JL; Hurtado-Monroy R; Vargas-Viveros P; Carrillo-Muñoz S; Candelaria-Hernández M
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S82-5. PubMed ID: 27521331
[TBL] [Abstract][Full Text] [Related]
7. Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.
Numata A; Kajiyama R; Itabashi M; Ishii Y; Yamamoto W; Motohashi K; Matsumoto K; Hagihara M; Ishigatsubo Y; Fujisawa S
Leuk Lymphoma; 2016; 57(1):201-2. PubMed ID: 25860242
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
[TBL] [Abstract][Full Text] [Related]
9. miR-505-5p and miR-193b-3p: potential biomarkers of imatinib response in patients with chronic myeloid leukemia.
Ramachandran SS; Muiwo P; Ahmad HM; Pandey RM; Singh S; Bakhshi S; Kumar L; Bhattacharya A; Gupta YK
Leuk Lymphoma; 2017 Aug; 58(8):1981-1984. PubMed ID: 28093001
[No Abstract] [Full Text] [Related]
10. The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations.
Soysal T; Eskazan AE; Serin I; Sadri S; Keskin D; Ozgur Yurttas N; Berk S; Erdogan Ozunal I; Salihoglu A; Ar MC; Ongoren S; Baslar Z; Ozbek U; Aydin Y
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e377-e384. PubMed ID: 31088736
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
12. Successful Management of a Pregnant Patient With Chronic Myeloid Leukemia Receiving Standard Dose Imatinib.
Stella S; Tirró E; Massimino M; Vitale SR; Russo S; Pennisi MS; Puma A; Romano C; DI Gregorio S; Innao V; Stagno F; DI Raimondo F; Musolino C; Manzella L
In Vivo; 2019; 33(5):1593-1598. PubMed ID: 31471409
[TBL] [Abstract][Full Text] [Related]
13. Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients.
Chandrasekhar C; Kumar PS; Sarma PVGK
Sci Rep; 2019 Feb; 9(1):2412. PubMed ID: 30787317
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.
Etienne G; Guilhot J; Rea D; Rigal-Huguet F; Nicolini F; Charbonnier A; Guerci-Bresler A; Legros L; Varet B; Gardembas M; Dubruille V; Tulliez M; Noel MP; Ianotto JC; Villemagne B; Carré M; Guilhot F; Rousselot P; Mahon FX
J Clin Oncol; 2017 Jan; 35(3):298-305. PubMed ID: 28095277
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone with imatinib in CML may reduce residual disease.
Brower V
Lancet Oncol; 2017 Feb; 18(2):e70. PubMed ID: 28089103
[No Abstract] [Full Text] [Related]
16. Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia.
Dragani M; Rege-Cambrin G; Ferrero D; Abruzzese E; Pregno P; Elena C; Cedrone M; Santoro M; Andreani G; Saglio G; Fava C
Leuk Lymphoma; 2019 Dec; 60(13):3330-3332. PubMed ID: 31161827
[No Abstract] [Full Text] [Related]
17. Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area.
Park SJ; Choi IK; Seo HY; Sung HJ; Park KH; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
Acta Haematol; 2007; 118(4):219-21. PubMed ID: 18057867
[No Abstract] [Full Text] [Related]
18. Imatinib mesylate- and dasatinib-induced eosinophilia in a patient with chronic myelocytic leukemia.
McGrath K; Stein B; Kalhagen L; Leighton L
Ann Allergy Asthma Immunol; 2017 Jul; 119(1):85-86. PubMed ID: 28499700
[No Abstract] [Full Text] [Related]
19. Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.
Khoury HJ; Goldberg SL; Mauro MJ; Stone RM; Deininger MW; Bradley-Garelik MB; Mohamed H; Guilhot F
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):341-349.e1. PubMed ID: 27133948
[TBL] [Abstract][Full Text] [Related]
20. Case with chronic myeloid leukemia and T315I mutation, but still in complete molecular response under high dose imatinib therapy.
Moro MI; Manrique G; Uriarte R; Díaz L
Leuk Lymphoma; 2014 Jul; 55(7):1684-6. PubMed ID: 24083818
[No Abstract] [Full Text] [Related]
[Next] [New Search]
